Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) said today that the FDA approved the companies’ new supplemental Biologics License Application for a once-monthly, 300 milligram dose of Praluent as a treatment for adults with high low-density lipoprotein cholesterol.
The 300 milligram dose is administered using 2 pre-filled pens that each deliver 150 milligrams at an injection site. The European Commission approved the once-monthly dose of Praluent (alirocumab) in November last year, Sanofi said.
Get the full story at our sister site, Drug Delivery Business News.